Primary biliary cholangitis treatment seladelpar meets primary endpoint in Phase III study

Seladelpar, a potent and selective peroxisome proliferator-activated receptor delta (PPARδ) agonist, demonstrated significant anti-cholestatic and anti-inflammatory effects in 78.2% of patients in the 10 mg group and 57.1% in the 5 mg group vs. 12.5% on placebo after 3 months.


Biospace Inc.